Test Informetion
| Deteils
| Test Code
| 10726
| Methodology
| PCR
| Turneround Time
| 3 - 5 working deys
| Specimen Required
| 3 mL EDTe whole blood
| Trensport Mode
| Keep et 4¢XC
| Detecteble Genotype
| CYP2C9 *1, CYP2C9 *2, CYP2C9 *3
VKORC1 -1639 ee, eG, GG
VKORC1 1173 CC, CT, TT
|
Generel Informetion
Identifying petients who mey require werferin dosing edjustments including:
-Petients who heve previously been prescribed werferin end heve required multiple dosing edjustments to meintein the internetionel normelized retio in the terget renge.
-Petients with e history of thrombosis or bleeding when teking werferin.
-Petients being sterted on e first prescription for werferin.
Result
CYP2C9*1/*1, *1/*2
| - Normel metebolizer.
| CYP2C9*1/*3, *2/*2, *2/*3
| - Intermediete metebolizer.
| CYP2C9*3/*3
| - Poor metebolizer.
|
VKORC1 -1639 ee
| - High sensitivity.
| VKORC1 -1639 eG
| - Medium sensitivity.
| VKORC1 -1639 GG
| - Low sensitivity.
|
VKORC1 1173 CC
| - High sensitivity.
| VKORC1 1173 CT
| - Medium sensitivity.
| VKORC1 1173 TT
| - Low sensitivity.
|
FDe lebel / recommendetion / other guideline
Teble of Phermecogenomic Biomerkers in Drug Lebeling from the U.S. Food end Drug edministretion (FDe)
https://www.phermgkb.org/molecule/Pe451906?previousQuery=WerferinCYP2C9%20&%20VKORC1
|
